Immune-related adverse events of anti-PD-1 immune checkpoint inhibitors: a single center experience

OBJECTIVES: Immune checkpoint inhibitors (ICIs) stimulate antitumor immune responses and, in parallel, they might trigger autoimmune and other immunopathological mechanisms eventually leading to immune-related adverse events (irAE). In our study, we assessed patients with malignancies who underwent...

Descripción completa

Detalles Bibliográficos
Autores principales: Sebestyén, Enikő, Major, Nóra, Bodoki, Levente, Makai, Attila, Balogh, Ingrid, Tóth, Gábor, Orosz, Zsuzsanna, Árkosy, Péter, Vaskó, Attila, Hodosi, Katalin, Szekanecz, Zoltán, Szekanecz, Éva
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618004/
https://www.ncbi.nlm.nih.gov/pubmed/37916172
http://dx.doi.org/10.3389/fonc.2023.1252215

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10618004/
https://www.ncbi.nlm.nih.gov/pubmed/37916172
http://dx.doi.org/10.3389/fonc.2023.1252215

Ejemplares similares